Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.98 | — | — | — | — | — | — | — | 66.71 | — | — | — | — | 35.05 | — | — | 12.91 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.52 | 1.67 | 2.62 | 3.90 | 2.84 | 3.02 | 2.41 | 3.95 | 2.66 | 4.14 | 5.93 | 9.24 | 10.48 | 4.12 | 8.16 | 21.81 | 3.13 | 9.85 | 8.50 | 74.84 | 30.80 |
| — | -44.6% | +8.7% | -1.4% | +6.5% | -27.0% | -59.4% | -57.2% | -74.6% | +0.3% | -27.2% | -57.6% | +235.1% | -58.2% | -4.0% | -70.9% | -89.9% | -66.4% | -76.5% | +1121.4% | +51.2% | |
| P/B Ratio | 4.16 | 5.21 | 8.49 | 9.91 | 8.51 | 8.64 | 6.74 | 8.04 | 7.14 | 10.27 | 11.83 | 11.28 | 8.63 | 4.86 | 5.92 | 7.91 | 5.62 | 2.94 | 1.62 | 2.18 | 1.53 |
| — | -39.7% | +26.0% | +23.2% | +19.1% | -15.9% | -43.0% | -28.7% | -17.3% | +111.1% | +99.9% | +42.6% | +53.6% | +65.5% | +265.5% | +262.3% | +266.1% | +74.1% | +0.1% | +77.0% | +31.3% | |
| P/FCF | — | 98.46 | — | — | 17.24 | 1594.40 | — | — | 33.56 | 1116.37 | — | — | — | — | — | — | 9.71 | — | — | — | — |
| — | -93.8% | — | — | -48.6% | +42.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 66.18 | — | — | 64.94 | 67.19 | — | — | 38.36 | 151.47 | — | — | — | 30.25 | — | — | 9.38 | — | — | — | — |
| — | -1.5% | — | — | +69.3% | -55.6% | — | — | — | +400.7% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 66.18 | — | — | 54.47 | 52.61 | — | — | 31.47 | 93.16 | — | — | — | 26.26 | — | — | 9.84 | — | — | — | — |
| — | +25.8% | — | — | +73.1% | -43.5% | — | — | — | +254.8% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.5% | 96.4% | 95.2% | 94.9% | 90.6% | 95.6% | 86.7% | 82.6% | 84.3% | 84.0% | 86.3% | 83.6% | 85.2% | 86.4% | 84.4% | 86.5% | 92.8% | 85.3% | 94.5% | 81.8% | 100.0% |
| — | +0.9% | +9.9% | +14.9% | +7.5% | +13.8% | +0.4% | -1.2% | -1.1% | -2.7% | +2.3% | -3.4% | -8.2% | +1.2% | -10.7% | +5.7% | -7.2% | -14.7% | -5.5% | -3.5% | +0.2% | |
| Operating Margin | -10.1% | 3.2% | -10.3% | -34.7% | 4.1% | 4.2% | -14.7% | -49.0% | 7.0% | 2.3% | -18.6% | -53.6% | -81.4% | 13.1% | -74.4% | -229.3% | 27.5% | -438.8% | -1037.8% | -5941.7% | -3427.9% |
| — | -25.5% | +30.3% | +29.2% | -41.8% | +86.1% | +20.8% | +8.5% | +108.6% | -82.7% | +75.0% | +76.6% | -396.3% | +103.0% | +92.8% | +96.1% | +100.8% | +87.8% | +69.6% | -1121.9% | -124.3% | |
| Net Margin | -15.1% | -0.6% | -13.8% | -39.8% | -0.3% | -0.9% | -19.5% | -55.5% | 4.0% | -0.8% | -22.5% | -57.6% | -83.8% | 11.8% | -76.7% | -235.5% | 24.2% | -459.1% | -1066.4% | -5998.1% | -3521.3% |
| — | +34.3% | +29.2% | +28.3% | -108.1% | -6.7% | +13.1% | +3.7% | +104.8% | -107.0% | +70.7% | +75.5% | -446.2% | +102.6% | +92.8% | +96.1% | +100.7% | +87.6% | +69.0% | -1090.8% | -120.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.2% | -0.5% | -11.2% | -23.8% | -0.3% | -0.7% | -13.4% | -25.8% | 2.8% | -0.5% | -11.0% | -16.7% | -16.1% | 4.2% | -13.8% | -23.9% | 12.9% | -38.2% | -46.0% | -38.2% | -44.2% |
| — | +28.6% | +16.0% | +7.6% | -109.0% | -24.5% | -21.1% | -54.5% | +117.4% | -112.6% | +19.8% | +30.2% | -224.3% | +111.0% | +70.0% | +37.4% | +129.3% | +12.8% | -26.3% | -48.2% | -96.9% | |
| ROA | -13.1% | -0.1% | -3.1% | -7.5% | -0.1% | -0.2% | -4.4% | -9.7% | 1.2% | -0.2% | -4.8% | -8.3% | -9.8% | 2.6% | -8.0% | -13.2% | 6.4% | -16.6% | -20.6% | -20.1% | -22.6% |
| — | +37.7% | +28.9% | +23.2% | -107.1% | +10.6% | +9.3% | -17.4% | +111.8% | -108.6% | +40.0% | +37.0% | -253.6% | +116.0% | +61.3% | +34.6% | +128.3% | +28.6% | +5.2% | -24.8% | -56.5% | |
| ROIC | -10.7% | 0.9% | -2.9% | -7.7% | 1.2% | 1.2% | -4.1% | -10.3% | 2.6% | 0.8% | -4.8% | -8.8% | -10.7% | 3.5% | -12.4% | -35.1% | 22.5% | -41.0% | -42.2% | -37.5% | -41.5% |
| — | -27.3% | +28.3% | +24.6% | -52.4% | +54.6% | +13.7% | -16.6% | +123.9% | -77.3% | +61.7% | +75.0% | -147.5% | +108.5% | +70.5% | +6.2% | +154.1% | -9.1% | -23.2% | -48.3% | -84.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.27 | 1.56 | 1.72 | 1.40 | 1.27 | 1.35 | 1.48 | 1.06 | 0.89 | 0.66 | 0.71 | 0.70 | 0.34 | 0.18 | 0.28 | 0.32 | 0.37 | 0.56 | 0.71 | 0.60 | 0.55 |
| — | +16.1% | +16.1% | +31.6% | +43.1% | +103.9% | +107.5% | +53.1% | +163.8% | +266.4% | +151.8% | +119.7% | -9.5% | -67.6% | -60.4% | -47.3% | -32.7% | -30.8% | +27.4% | +48.7% | +25.3% | |
| Debt / EBITDA | — | 63.72 | — | — | 35.15 | 37.25 | — | — | 17.76 | 37.63 | — | — | — | 4.48 | — | — | 2.77 | — | — | — | — |
| — | +71.0% | — | — | +97.9% | -1.0% | — | — | — | +740.1% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.31 | 3.45 | 3.34 | 3.49 | 4.31 | 4.41 | 4.30 | 4.12 | 4.58 | 4.03 | 4.21 | 4.53 | 4.88 | 5.54 | 2.63 | 2.65 | 2.34 | 2.31 | 2.34 | 2.39 | 2.53 |
| — | -21.7% | -22.3% | -15.5% | -5.8% | +9.5% | +2.1% | -9.1% | -6.2% | -27.3% | +60.3% | +71.2% | +108.6% | +140.2% | +12.2% | +10.9% | -7.5% | +3.5% | -27.4% | -51.4% | -63.2% | |
| Quick Ratio | 4.11 | 3.26 | 3.15 | 3.28 | 4.11 | 4.11 | 4.03 | 3.81 | 4.31 | 3.87 | 3.99 | 4.36 | 4.64 | 5.35 | 2.50 | 2.57 | 2.29 | 2.28 | 2.25 | 2.31 | 2.53 |
| — | -20.6% | -21.9% | -14.0% | -4.5% | +6.3% | +0.9% | -12.6% | -7.1% | -27.6% | +59.4% | +69.5% | +102.4% | +134.1% | +11.3% | +11.1% | -9.4% | +2.4% | -30.3% | -52.9% | -63.2% | |
| Interest Coverage | -1.14 | 0.54 | -2.35 | -4.44 | 0.95 | 0.89 | -1.90 | -5.43 | 1.80 | 0.85 | -2.34 | -5.50 | -9.15 | 4.37 | -7.38 | -12.40 | 6.87 | -12.33 | -33.22 | -36.63 | -35.82 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARDX stock.
Ardelyx, Inc.'s current P/E is -13.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ardelyx, Inc.'s current operating margin is -10.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ardelyx, Inc.'s business trajectory between earnings reports.